Batazu Advanced Therapeutics is developing BAT-33/CLL1, Europe’s first dual-target CAR-T therapy designed specifically for AML. BAT-33/CLL1 provides several improvements to overcome barriers that have delayed CAR-T cell therapy success: widening the patient population, reducing the possibility of antigen escape, and expediting CAR-T cell manufacture
Approach
Out technology is based in 3 pillars:
Pillar 1
BAT-33/CLL1 Dual-Target CAR-T
BAT-33/CLL1 is a multi-specific, OR-gated CAR-T cell therapy that recognises CD33, CLL-1 or both on leukemic cells. By activating as soon as either antigen is present, it can eliminate highly heterogeneous AML populations and block the main cause of CAR-T failure in AML: antigen escape.
This design achieves very broad AML coverage (over 90% of cases, especially in children) while delivering rapid, deep tumour clearance in preclinical models.
Pillar 2
Rapid Expansion-Less Manufacturing
BAT-33/CLL1 is produced with an ultra-rapid process: fresh T cells are transduced overnight and formulated directly, without prolonged ex-vivo expansion.
This next-generation process cuts manufacturing time from 6–8 weeks to about less than two week vein-to-vein and can reduce significantly the manufacturing costs, making CAR-T more accessible for European hospitals and health systems.
Pillar 3
A 3-Step AML Patient Journey Aimed at Cure
BAT-33/CLL1 is designed to fit into a planned treatment pathway rather than a stand-alone intervention:
- Chemotherapy to debulk disease and create space in the bone marrow.
- BAT-33/CLL1 CAR-T to eradicate residual leukemic cells expressing CD33 and/or CLL-1 and achieve deep remission within the narrow pre-transplant window.
- Allogeneic stem cell transplant (HSCT) to rebuild a healthy blood and immune system and provide long-term graft-versus-leukaemia protection.
